More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis

Inflammatory Bowel Diseases

Volumn 15, Issue 9, 2009, Pages 1331-1336

  Claessen, M M H ^a   Lutgens, M W M D ^a   Van Buuren, H R ^b   Oldenburg, B ^a   Stokkers, P C F ^c   Van Der Woude, C J ^a   Hommes, D W ^d   De Jong, D J ^e   Dijkstra, G ^f   Van Bodegraven, A A ^g   Siersema, P D ^a   Vleggaar, Frank P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Inflammatory bowel disease; Primary sclerosing cholangitis

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CAUSE OF DEATH; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DATA BASE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; ADOLESCENT; CHILD; CLINICAL TRIAL; COLORECTAL TUMOR; DIFFERENTIAL DIAGNOSIS; ENTERITIS; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; SCLEROSING CHOLANGITIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CHOLANGITIS, SCLEROSING; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 70449723113     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20886     Document Type: Article

References (42)

1. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980;21:870-877.
2. Thorpe ME, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis. Gut. 1967;8:435-448.
3. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis. 1991;11:31-39.
4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535. (Pubitemid 32234798)
5. Lutgens MW, van der Heijden GJ, Vleggaar FP, et al. A comprehensive meta-analysis of the risk of colorectal cancer in ulcerative colitis and Crohn's disease. Gastroenterology. 2008;134:A33-A34.
6. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22:1404-1408.
7. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997;41:522-525. (Pubitemid 27448786)
8. Claessen MMH, Vleggaar FP, Tytgat KMAJ, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2008;50:158-164.
9. Hill MJ, Melville DM, Lennard-Jones JE, et al. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet. 1987;25:185-186. (Pubitemid 17091851)
10. Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999;94:1643-1649. (Pubitemid 29260459)
11. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91-96. (Pubitemid 40007225)
12. Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19-24. (Pubitemid 46535194)
13. Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut. 2008;57:1246-1251
14. MacCarty RL, LaRusso NF, Wiesner RH, et al. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology. 1983;149:39-44.
15. Ludwig J, Barham SS, LaRusso NF, et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology. 1981;1:632-640. (Pubitemid 12218457)
16. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931-968. (Pubitemid 14209714)
17. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51(suppl 5):V10-V12.
18. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology. 2003;124:544-560. (Pubitemid 36169269)
19. AJCC Cancer Staging Manual. 6th ed. New York: AJCC; 2002.
20. Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1997;92:1285-1288. (Pubitemid 27328584)
21. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 2001;44:77-85. (Pubitemid 32105878)
22. Nagengast FM, Grubben MJ, van Munster I. Role of bile acids in colorectal carcinogenesis. Eur J Cancer. 1995;31A:1067-1070.
23. Bayerdorffer E, Mannes GA, Ochsenkuhn T, et al. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut. 1995;36:268-273.
24. Kishida T, Taguchi F, Feng L, et al. Analysis of bile acids in colon residual liquid or fecal material in patients with colorectal neoplasia and control subjects. J Gastroenterol. 1997;32:306-311. (Pubitemid 27254796)
25. Summerton J, Flynn M, Cooke T, et al. Bile acid receptors in colorectal cancer. Br J Surg. 1983;70:549-551.
26. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889-893. (Pubitemid 36389790)
27. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;16:89-95.
28. Jazrawi RP, de Caestecker JS, Goggin PM, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology. 1994;106:134-142.
29. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525-531. (Pubitemid 34977162)
30. Rost D, Rudolph G, Kloeters-Plachky P, et al. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology. 2004;40:693-698. (Pubitemid 39265592)
31. Stiehl A, Rudolph G, Sauer P, et al. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol. 1995;23:283-289.
32. Beuers U, Spengler U, Zwiebel FM, et al. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology. 1992;5:603-608.
33. Loftus EV Jr, Aguilar HI, Sandborn WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology. 1998;27:685-690. (Pubitemid 28103543)
34. Gervaz P, Bouzourene H, Cerottini JP, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum. 2001;44:364-372. (Pubitemid 32226325)
35. Sugai T, Habano W, Jiao YF, et al. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. J Mol Diagn. 2006;8:193-201. (Pubitemid 43811242)
36. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116:1453-1456. (Pubitemid 29258894)
37. Brentnall TA, Crispin DA, Bronner MP, et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 1996;15:1237-1240. (Pubitemid 26080961)
38. Itzkowitz SH. Microsatellite instability in colitis associated colorectal cancer. Gut. 2000;46:304-305.
39. Lyda MH, Noffsinger A, Belli J, et al. Microsatellite instability and K-ras mutations in patients with ulcerative colitis. Hum Pathol. 2000;31:665-671. (Pubitemid 30445468)
40. Suzuki H, Harpaz N, Tarmin L, et al. Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Res. 1994;15:4841-4844. (Pubitemid 24289411)
41. Willenbucher RF, Aust DE, Chang CG, et al. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol. 1999;154:1825-1830.
42. Broome U, Lofberg R, Lundqvist K, et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum. 1995;38:1301-1305.